Description

Product Description: GLP-2 (T) — Advanced Dual Incretin Research Peptide for Metabolic and Weight Management Studies

Explore the next evolution in metabolic research with GLP-2 (T) — a cutting-edge dual incretin peptide designed for advanced scientific study in the areas of glucose regulation, energy balance, and metabolic efficiency.

This research peptide exhibits dual receptor activity, interacting with both GIP and GLP-1 pathways, making it a valuable compound for researchers investigating weight management, glycemic function, and appetite signaling mechanisms.

Key Research Highlights

✅ Supports Weight Management Research – Demonstrates enhanced fat-metabolism activity compared to single incretin analogs.

✅ Promotes Glucose Balance Studies – Shows potential to influence insulin sensitivity and glycemic regulation pathways.

✅ Appetite & Satiety Mechanisms – Dual incretin activity contributes to reduced food intake signals in controlled studies.

✅ Extended Half-Life – Designed for long-acting, once-weekly administration models in laboratory settings.

✅ Cardiometabolic Focus – Evaluated in research for potential roles in lipid regulation, blood pressure, and inflammatory balance.

Unlock the power of dual incretin synergy with GLP-2 (T) — a premier choice for scientists studying peptide-based approaches to metabolic health, body composition, and energy regulation.

---

Scientific Overview of GLP-2 (T)

GLP-2 (T) is a synthetic dual incretin peptide that engages both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors — often referred to in literature as a “twincretin” model compound. Structurally, it’s composed of 39 amino acids based on a modified GIP backbone, with acylation enhancements (C20 fatty diacid chain) that extend its half-life to approximately five days.

Mechanistically, GLP-2 (T) activates both receptor pathways:

• GLP-1 receptor engagement supports glucose-dependent insulin release, gastric emptying delay, and appetite regulation.

• GIP receptor activation complements these effects, promoting additional insulin sensitivity and lipid metabolism pathways.

Pharmacokinetic data from peer-reviewed research demonstrate linear dose response, with steady-state equilibrium achieved after approximately four weeks of consistent administration.

In published studies, dual incretin analogs like GLP-2 (T) have shown remarkable potential in improving insulin responsiveness, enhancing energy balance, and reducing adiposity markers when compared with single-pathway incretin peptides.

Note: GLP-2 (T) is intended for research use only. It is not approved for human consumption, diagnostic, or therapeutic applications.